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1.  Introduction 
A higher complication rate of Covid-19 infections in hematological malignancies, as a 
result of compromised immune responses associated with disease or therapy has 
been suggested. [1]  Indeed, from the outset of the pandemic, and prior to the 
publication of these data [1], changes to drug schedules and life-style, to reduce risk 
have been recommended by disease-expert groups (https://b-s-h.org.uk/about-
us/news/covid-19-updates).  While several factors including the potential for 
contracting or transmitting infection during hospital visits and challenges in delivery 
of care have influenced these recommendations, a significant driver for change has 
been the perceived level of immunosuppression in patients with hematological 
cancers.  The scientific rationale for these recommendations is sound, but emerging 
data indicate that the frequency of Covid-19 complications in patients on 
immunosuppression for autoimmune disorders is not different from the baseline 
population.[2,3]  Recent reports on cancer patients including hematological 
malignancies too suggest that anti-cancer therapies are unlikely to worsen Covid-19 
infections. [4,5]. 
 The urgency of data reporting has however resulted in these reports lacking 
treatment details, [5] and with limited follow-up, little is known about the 
consequences of further therapy, particularly relevant to patients with acute 
leukemia.  Here, we present information on 4 patients diagnosed with Covid-19 
infection, all of whom remained relatively asymptomatic despite significant 
immunocompromise.  We also report longitudinal changes in Covid-19 PCR cycle 
threshold (Ct) values in two patients who subsequently received additional cycles of 




2.  Methods 
2.1 Patients 
Data on 4 patients with Covid-19 infection were reviewed.  Part of the dataset was 
submitted to the UK Coronavirus Cancer Monitoring Project. [5]  Two outpatients 
presented with low-grade fever and two (Patients 3 and 4) tested ‘positive’ during in-
patient screening.  All patients were in complete remission prior to Covid-19 
detection from combined nasal and pharyngeal swabs. 
 
2.2 Laboratory detection of Covid-19 
Following nucleic acid extraction, a one-step reverse transcription PCR assay (RT-
PCR) targeting the RNA-dependent RNA polymerase (RdRP) gene was carried out 
using an ABI7500.  Testing with the AllplexTM 2019-nCoV Assay (Seegene, 
SouthKorea®) was subsequently introduced.  This assay targets N-(viral 
nucleocapsid protein) gene, RdRP gene and E-gene (viral envelope) and was 
carried out using the automated Seegene STARlet system®.  Samples with a Ct 
value ≥35 were reported as ‘detected at low level’ and a value of ≥40 was arbitrarily 
assigned as being ‘negative’. 
 
Since hospital infection and control policies required patients to test PCR 
‘negative’ on two consecutive swab specimens before re-admission to ‘non-Covid’ 
units, we were able to obtain serial Ct values for RdRP using the ABI7500 or 
AllplexTM 2019-nCoV assays in patients 3 and 4.  Since Ct values for Covid-19 have 
been suggested to be an inverse surrogate for viral load, we related Ct values to 
changes in the blood neutrophil, lymphocyte and monocyte count, on or within 3 
days of swabbing patients. 
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3.  Results 
3.1 Patient demographics, treatment and outcomes 
A summary of the patients’ hematological diagnosis, anti-cancer therapies and 
Covid-19 infection is presented in Table 1.  Patients 1 and 2 were discharged from 
hospital after overnight observation and the in-patients were transferred to a Covid 
Unit for continued monitoring.  Marrow recovery was not delayed in either patient.  
To maintain optimal treatment-intensity, both started their subsequent cycles of 
chemotherapy despite persistent PCR positivity: Patient 3 commenced fludarabine-
containing chemotherapy (FLAG-Ida) and Patient 4 received interim maintenance 
with vincristine, dexamethasone, methotrexate and 6-mercaptopurine, uneventfully. 
 
3.2  Changes in Ct values 
The mean Ct value at diagnosis was 20.72 (18.28 - 31.15).  Patient 1, with the 
lowest Ct value at diagnosis and on no medication tested ‘negative’ on repeat 
sampling undertaken after one month.  Patient 2 continued cyclosporine without 
dose adjustments and tested ‘negative’ after 17 days.  However, she re-tested ‘low 
positive’ (Ct 37.96) 42 days after the original detection of Covid-19, but without 
symptoms.  Changes in Ct values in the two in-patients (Patients 3 and 4) are shown 
in Figure 1A and can be compared to the absolute lymphocyte count (ALC) at the 
corresponding time-points (Figure 1B).  In a total of 18 measurements on both 
patients (12 and 6 respectively), Ct values correlated with numbers of circulating 
lymphocytes (r=0.69, p=0.001) and monocytes (r=0.59, p=0.01), but not neutrophils 
(r=0.19, p=0.43), in response to therapy. 
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4.  Discussion 
The relatively indolent infection in our patients despite recent myelosuppression and 
the likelihood of significant immunocompromise adds to the growing body of 
literature that suggests that it may be simplistic to attribute the complications of 
Covid-19 infections to immunosuppression associated with hematological 
malignancy or its therapy. [4,5]  Many reports on Covid-19 complications in cancer 
patients have suffered with unavoidable selection bias through the inclusion of 
hospitalised patients and small numbers of patients with hematological cancers, with 
advanced age, co-morbidity, disease stage and therapies further confounding 
analysis and interpretation. [1]  Focussed reports of Covid-19 infections in 
hematological malignancies [6,7] too have been confounded by age, sex or disease-
stage (newly diagnosed or relapsed/refractory), often associated with frailty that pre-
disposes to severe infections. 
The details of our experience along with outputs from larger, recent datasets 
[4,5] argue against the risk of Covid-19 complications being a consequence of 
immunosuppression.  Changes in referral patterns notwithstanding, preliminary data 
from the Intensive Care National Research and Audit Centre suggest that the 
proportion of critically ill Covid-19 infected patients with hematological malignancies 
or immunosuppression is lower than in a historic cohort of patients with non-Covid-
19 viral pneumonia, to further support our observations. 
(https://www.icnarc.org/DataServices/Attachments/Download/da19fd54-70b2-ea11-
9127-00505601089b).  Based on the observation of correlation between longitudinal 
changes in Ct values and the ALC following Covid-19 diagnosis, we cautiously 
suggest that immunosuppression may potentially delay clearance of Covid-19, [8] 
but this hypothesis requires confirmation with a truly quantitative RT-PCR assay 
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taking into account the validity of the standard curve with reference materials or in-
house plasmid controls with assigned  viral copy numbers [9] before the clinical 
significance can be ascertained.  Supporting the expert panel recommendations for 
disease management during the Covid-19 pandemic, [10] our report emphasizes the 
importance of adapting anti-cancer therapies to each patient’s needs, but without 
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Table 1.  Patient characteristics at time of detection of Covid-19. 
No. Age 
(years) 





           
1 66 Male hypertension, 
hyperlipidemia 
  




1.3 1.5 fever resolved < 24 
hours 
          














3.5 1.6 cough/fever resolved < 24 
hours 
           











0.1 0.1 anosmia resolved < 7 
days 
           
4 23 Male nil B-acute lymphoblastic 
leukemia 









0.4 0.5 none remained 
asymptomatic 




Figure 1.  Longitudinal changes in Covid-19 RT-PCR Ct values and absolute 
lymphocyte count (ALC).  Ct values from the day of diagnosis of Covid-19 infection 
(day 0) are shown in two patients until last follow-up (Patient 3) or a negative result 
(Patient 4) (A), along with the day of starting further chemotherapy (    for Patient 3 
and     for Patient 4).  Changes in Ct correlated with the absolute lymphocyte count 
(ALC) measured on or within 3 days of nasal and pharyngeal swab testing (B) to 
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